TargetMol

Lirilumab

Product Code:
 
TAR-T77423
Product Group:
 
Primary Antibodies
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
 

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T77423-1mg1mg£275.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T77423-5mg5mg£607.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T77423-10mg10mg£930.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T77423-25mg25mg£1,348.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T77423-50mg50mg£1,781.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T77423-100mg100mg£2,392.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPv + cervical cancer activity of natural killer cells through vAv1-dependent NF-κB deinhibition. It can be used to study leukemia, head and neck squamous cell carcinoma (SCCHN).
CAS Number:
1000676-41-4
Purity:
SDS-PAGE: 95%; SEC-HPLC: 98.4%
Target:
virus Protease

Documents

References

1.Kohrt HE, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014 Jan 30;123(5):678-86. 2.Hanna GJ, et al. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478.